Publications by authors named "P Khankhanian"
Article Synopsis
- The study investigates the genetic and environmental factors influencing susceptibility to multiple sclerosis (MS) specifically in the Canadian population.
- It distinguishes between directly observable epidemiological data (like the prevalence of MS among siblings and sex ratios) and inferred data (like genetic susceptibility) to better understand the disease's dynamics.
- Using advanced modeling techniques, the research reveals that only a small fraction of the population (≤ 52%) and an even smaller fraction of women (< 32%) are genetically susceptible to MS, suggesting that most individuals are unlikely to develop the disease regardless of environmental factors.
Background And Objectives: To describe the prevalence of high adverse childhood experiences (ACEs) among neurology outpatients and determine their association with health care utilization rates and comorbid medical and psychiatric disease.
Methods: This was a cross-sectional study of adults seen for outpatient neurology follow-up at the University of Pennsylvania. Participants completed the ACE questionnaire and depression/anxiety screenings.
Objective: To develop a natural language processing (NLP) algorithm to abstract seizure types and frequencies from electronic health records (EHR).
Background: Seizure frequency measurement is an epilepsy quality metric. Yet, abstraction of seizure frequency from the EHR is laborious.
The vagus nerve stimulator (VNS) and responsive nerve stimulator (RNS) are nonpharmacological devices approved for drug-resistant epilepsy. Vagus nerve stimulator was removed before placing an RNS in clinical trials. Two cases of bilateral mesial temporal epilepsy treated concurrently with VNS and bilateral mesial temporal RNS devices were reported.
View Article and Find Full Text PDFObjectives: To evaluate the effectiveness and tolerability of clobazam as an adjunctive treatment for adults with drug-resistant epilepsy.
Methods: We performed a single-center, retrospective chart review of patients aged ≥18 years with drug-resistant epilepsy who started clobazam between 2010 and 2018. Included patients had outpatient visits both before and ≥1 month after clobazam initiation.